drugset
drugset / Trial / NCT01215747

Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis

NCT01215747 ↗

Phase 3 Completed 261 enrolled C.T. Development America, Inc.
RandomizedParallel-groupDouble-blindPrevention

Summary

The primary purpose of this study is to assess the efficacy and safety of treatment with Kiacta in adult patients with AA Amyloidosis.

Timeline

Start
2010-11
Primary completion
2016-01
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject eprodisate Small molecule 400 mg Oral

Indications

amyloidosis